B

Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315

Watchlist Manager
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Watchlist
Price: 8.25 HKD -2.02% Market Closed
Market Cap: 3.3B HKD
Have any thoughts about
Biocytogen Pharmaceuticals Beijing Co Ltd?
Write Note

Biocytogen Pharmaceuticals Beijing Co Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biocytogen Pharmaceuticals Beijing Co Ltd
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
B
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Additional Paid In Capital
ÂĄ2B
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Additional Paid In Capital
ÂĄ81.4B
CAGR 3-Years
15%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Additional Paid In Capital
ÂĄ27.5B
CAGR 3-Years
7%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Additional Paid In Capital
ÂĄ3.3B
CAGR 3-Years
95%
CAGR 5-Years
81%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Additional Paid In Capital
ÂĄ3.5B
CAGR 3-Years
-1%
CAGR 5-Years
90%
CAGR 10-Years
N/A
No Stocks Found

Biocytogen Pharmaceuticals Beijing Co Ltd
Glance View

Market Cap
3.3B HKD
Industry
Biotechnology

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. The company is headquartered in Beijing, Beijing. The company went IPO on 2022-09-01. The firm operates two business segments. The Drug Development Business segment is mainly engaged in the research and development of oncology and autoimmune disease treatments, as well as antibody development. The Preclinical Research Service segment is mainly engaged in gene editing, preclinical pharmacological efficacy evaluation and model animal sales.

Intrinsic Value
11.01 HKD
Undervaluation 25%
Intrinsic Value
Price
B

See Also

What is Biocytogen Pharmaceuticals Beijing Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
2B CNY

Based on the financial report for Dec 31, 2023, Biocytogen Pharmaceuticals Beijing Co Ltd's Additional Paid In Capital amounts to 2B CNY.

What is Biocytogen Pharmaceuticals Beijing Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 3Y
18%

Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for Biocytogen Pharmaceuticals Beijing Co Ltd have been 18% over the past three years .

Back to Top